All In Biotech

Drug Trial Radar · NCT00342381

Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation

Fatigue in Multiple Sclerosis: Evaluated With 3 Tesla MRI and Transcranial Magnetic Stimulation

Last checked: Nov 20, 2026Latest source record: Dec 17, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 2006

Primary completion

Not stated

Study completion Dec 2007

Sponsor

Lead sponsor
University of AarhusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Danish Multiple Sclerosis Society
First posted
Jun 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate fatigue in patients with multiple sclerosis (MS) and to determine the correlation between the symptom and cerebral changes.

Conditions

  • Multiple Sclerosis
  • Fatigue

Interventions

  • 3,4-diaminopyridineDrug

    Single dose 3,4 diaminopyridine

  • PlaceboDrug

    Single dose placebo treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Subjective fatigue (FSS)Time frame: Weeks
  2. Maximal voluntary isometric contraction, central activation before and after exerciseTime frame: at the time of investigation
  3. Digit Symbol-Coding scoresTime frame: Weeks
  4. Changes in normal appearing white matter and normal appearing gray matter (MRS-, MTI- and DTI- parameters)Time frame: at the time of MRI
  5. Cortical atrophyTime frame: at the time of MRI
  6. Intracortical inhibition/facilitation determined by transcranial magnetic stimulation (+/- 3,4-diaminopyridine)Time frame: at the time of investigation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Aarhus University Hospital, Department of Neurology

    Aarhus, Denmark

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.